SBSubhomoi Borkotoky

Subhomoi Borkotoky

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Subhomoi Borkotoky has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Structure-Based Virtual Screening and Pharmacokinetic Prioritization of Natural Compounds with Predicted Binding to the Endothelial Protein C Receptor in Cerebral Malaria

    by Shivani Malik, Subhomoi Borkotoky, Savitri Tiwari, Reetesh Kumar

    The Endothelial Protein C Receptor (EPCR) is a transmembrane glycoprotein expressed on vascular endothelial cells. In cerebral malaria, binding of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) variants containing CIDRα1 domains can interfere with these protective interactions. We used virtual screening, molecular docking, MD simulations, and normal mode analysis to assess 87,489 natural compounds from the ZINC database. ZINC04084408, ZINC04084805, and ZINC04085245 were prioritized as candidate EPCR-binding compounds through the computational workflow. Their predicted poses generate hypotheses for experimental evaluation but do not establish inhibition of PfEMP1–EPCR interaction, effects on protein C activation or activated protein C (APC)-mediated signaling, or therapeutic efficacy. Following AutoDock Vina screening, ten compounds shared the lowest reported docking score of −13.9 kcal/mol and were advanced for detailed AutoDock 4.1 docking and pharmacokinetic evaluation. ZINC04084408, ZINC04084805, and ZINC04085245 were subsequently prioritized based on selected physicochemical and pharmacokinetic criteria. These compounds were predicted to occupy the hydrophobic ligand-binding pocket of EPCR. However, the calculations do not demonstrate selective EPCR binding or competitive inhibition of the PfEMP1–EPCR interaction. The predicted low aqueous solubility and model-dependent toxicity results represent important development limitations. The three compounds remain computationally prioritized candidates requiring experimental binding, toxicological, and functional validation.

  • Open Access

    Stabilizing the Shield: C-Terminal Tail Mutation of HMPV F Protein for Enhanced Vaccine Design

    by Reetesh Kumar, Subhomoi Borkotoky, Rohan Gupta, Jyoti Gupta, Somnath Maji, Savitri Tiwari, Rajeev K. Tyagi, Baldo Oliva

    Background: Human Metapneumovirus (HMPV) is a respiratory virus in the Pneumoviridae family. HMPV is an enveloped, negative-sense RNA virus encoding three surface proteins: SH, G, and F. The highly immunogenic fusion (F) protein is essential for viral entry and a key target for vaccine development. The F protein exists in two conformations: prefusion and postfusion. The prefusion form is highly immunogenic and considered a potent vaccine antigen. However, this conformation needs to be stabilized to improve its immunogenicity for effective vaccine development. Specific mutations are necessary to maintain the prefusion state and prevent it from changing to the postfusion form. Methods: In silico mutagenesis was performed on the C-terminal domain of the pre-F protein, focusing on five amino acids at positions 469 to 473 (LVDQS), using the established pre-F structure (PDB: 8W3Q) as the reference. The amino acid sequence was sequentially mutated based on hydrophobicity, resulting in mutants M1 (IIFLL), M2 (LLIVL), M3 (WWVLL), and M4 (YMWLL). Increasing hydrophobicity was found to enhance protein stability and structural rigidity. Results: Epitope mapping revealed that all mutants displayed significant B and T cell epitopes similar to the reference protein. The structure and stability of all mutants were analyzed using molecular dynamics simulations, free energy calculations, and secondary structure analysis. Based on the lowest RMSD, clash score, MolProbity value, stable radius of gyration, and low RMSF, the M1 mutant demonstrated superior structural stability. Conclusions: Our findings indicate that the M1 mutant of the pre-F protein could be the most stable and structurally accurate candidate for vaccine development against HMPV.